Captain's Log: ASCO Day 3.
Today's episode brought myriad developments in treating CNS cancers and brain metastases from other distant lands. Some studies offered new and exciting targets for potential treatments. Others purported to provide benefits in new and exciting ways, eschewing infusions and tablets with vaccinations. Still, others repurposed old technology in new ways, investigating uses for things we already had.
Unfortunately, many of the solutions were premature and primitive in their exploration. Much further study is required. We will continue to observe these trials for outcomes, but we hope they will yield answers in our quest to fight the disease plaguing our crew.
Studies discussed:
Anti-PD-1 + GITR + RTx: https://meetings.asco.org/abstracts-presentations/218240
UCPVax: https://meetings.asco.org/abstracts-presentations/219832
Pembrolizumab in CNS metastases: https://meetings.asco.org/abstracts-presentations/218261
Many thanks to Merck for supporting this episode. Merck provided virtual access to ASCO 2023 but did not review or approve any part of OftiM's coverage of ASCO.
For more episodes, resources and blog posts, visit www.inquisitiveonc.com
Find us on Twitter @InquisitiveOnc!
If you want us to look at a specific trial or subject, email us atinquisitiveonc@gmail.com
Art courtesy of Taryn Silver
Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/
Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.
Hosted on Acast. See acast.com/privacy for more information.
